Astria Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2016 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Astria Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2016 to Q2 2024.
  • Astria Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 4.63 %, a 15.5% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 4.63 +0.62 +15.5% Jun 30, 2024
Q1 2024 3.88 -0.63 -14% Mar 31, 2024
Q4 2023 4.11 -0.9 -18% Dec 31, 2023
Q3 2023 3.95 -1.22 -23.6% Sep 30, 2023
Q2 2023 4.01 -0.48 -10.7% Jun 30, 2023
Q1 2023 4.52 +0.73 +19.3% Mar 31, 2023
Q4 2022 5.01 -2.95 -37.1% Dec 31, 2022
Q3 2022 5.17 -6.69 -56.4% Sep 30, 2022
Q2 2022 4.49 -17.3 -79.4% Jun 30, 2022
Q1 2022 3.79 -70.7 -94.9% Mar 31, 2022
Q4 2021 7.96 -5.42 -40.5% Dec 31, 2021
Q3 2021 11.9 -1.48 -11.1% Sep 30, 2021
Q2 2021 21.8 +8.72 +66.8% Jun 30, 2021
Q1 2021 74.5 +61.5 +472% Mar 31, 2021
Q4 2020 13.4 +0.57 +4.45% Dec 31, 2020
Q3 2020 13.3 +1.57 +13.3% Sep 30, 2020
Q2 2020 13.1 +2.27 +21% Jun 30, 2020
Q1 2020 13 +2.45 +23.2% Mar 31, 2020
Q4 2019 12.8 -1.2 -8.57% Dec 31, 2019
Q3 2019 11.8 -6.85 -36.8% Sep 30, 2019
Q2 2019 10.8 -17.2 -61.5% Jun 30, 2019
Q1 2019 10.6 -35.3 -77% Mar 31, 2019
Q4 2018 14 -30.5 -68.5% Dec 31, 2018
Q3 2018 18.6 -22.9 -55.2% Sep 30, 2018
Q2 2018 28 -9.6 -25.5% Jun 30, 2018
Q1 2018 45.8 +9.64 +26.6% Mar 31, 2018
Q4 2017 44.5 +10.7 +31.7% Dec 31, 2017
Q3 2017 41.6 +10.7 +34.5% Sep 30, 2017
Q2 2017 37.6 +9.41 +33.4% Jun 30, 2017
Q1 2017 36.2 +11 +43.8% Mar 31, 2017
Q4 2016 33.8 Dec 31, 2016
Q3 2016 30.9 Sep 30, 2016
Q2 2016 28.2 Jun 30, 2016
Q1 2016 25.2 Mar 31, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.